XNCR - Xencor, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
30.25
-0.75 (-2.42%)
At close: 4:00PM EDT

30.25 0.00 (0.00%)
After hours: 4:25PM EDT

Stock chart is not supported by your current browser
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Bearishpattern detected
Momentum

Momentum

Performance Outlook
  • Short Term
    2W - 6W
  • Mid Term
    6W - 9M
  • Long Term
    9M+
Previous Close31.00
Open30.83
Bid28.23 x 900
Ask32.91 x 800
Day's Range29.27 - 31.00
52 Week Range19.35 - 46.33
Volume428,701
Avg. Volume473,824
Market Cap1.724B
Beta (5Y Monthly)1.01
PE Ratio (TTM)N/A
EPS (TTM)-1.08
Earnings DateAug 06, 2020 - Aug 11, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est44.25
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
Near Fair Value
13% Est. Return
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
View more
  • Thomson Reuters StreetEvents

    Edited Transcript of XNCR earnings conference call or presentation 7-May-20 8:30pm GMT

    Q1 2020 Xencor Inc Earnings Call

  • Xencor to Present at Upcoming Investor Conferences
    Business Wire

    Xencor to Present at Upcoming Investor Conferences

    Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced that Bassil Dahiyat, Ph.D., president and chief executive officer, will participate in two upcoming investor conferences:

  • Xencor to Present Data from Four Preclinical XmAb® 2+1 Bispecific Antibody and Cytokine Programs at AACR Virtual Annual Meeting II
    Business Wire

    Xencor to Present Data from Four Preclinical XmAb® 2+1 Bispecific Antibody and Cytokine Programs at AACR Virtual Annual Meeting II

    Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced it will present new preclinical data on three XmAb® 2+1 bispecific antibody programs and an IL-12-Fc cytokine program at the second session of the American Association for Cancer Research (AACR) Virtual Annual Meeting, being held June 22-24, 2020. Abstracts for these poster presentations are now available on AACR’s website.

  • Xencor Reports Initial Dose-Escalation Data from Phase 1 Study of XmAb®20717, PD-1 x CTLA-4 Bispecific Antibody, in Solid Tumors
    Business Wire

    Xencor Reports Initial Dose-Escalation Data from Phase 1 Study of XmAb®20717, PD-1 x CTLA-4 Bispecific Antibody, in Solid Tumors

    Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today reported initial dose-escalation data from the Phase 1 study evaluating XmAb®20717, a PD-1 x CTLA-4 bispecific antibody and Xencor’s first tumor microenvironment activator, in patients with advanced solid tumors (DUET-2). The American Society of Clinical Oncology (ASCO) has published an abstract (e15001) with initial clinical data from the study on its website today.

  • Xencor to Present at the 2020 RBC Capital Markets Global Healthcare Virtual Conference
    Business Wire

    Xencor to Present at the 2020 RBC Capital Markets Global Healthcare Virtual Conference

    Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today announced that Bassil Dahiyat, Ph.D., president and chief executive officer, will participate in a fireside chat at the 2020 RBC Capital Markets Global Healthcare Virtual Conference on Wednesday, May 20, 2020 at 4:15 p.m. ET / 1:15 p.m. PT.

  • Growth Investors: Industry Analysts Just Upgraded Their Xencor, Inc. (NASDAQ:XNCR) Revenue Forecasts By 22%
    Simply Wall St.

    Growth Investors: Industry Analysts Just Upgraded Their Xencor, Inc. (NASDAQ:XNCR) Revenue Forecasts By 22%

    Xencor, Inc. (NASDAQ:XNCR) shareholders will have a reason to smile today, with the analysts making substantial...

  • Xencor Inc (XNCR) Q1 2020 Earnings Call Transcript
    Motley Fool

    Xencor Inc (XNCR) Q1 2020 Earnings Call Transcript

    Today on our call, Bassil Dahiyat, President and Chief Executive Officer; will provide updates regarding COVID-19, our portfolio programs and licensing partnerships; John Kuch, Senior Vice President and Chief Financial Officer, will review the financial results from the first quarter. Then we will open up the call for your question, and Allen Yang, Senior Vice President and Chief Medical Officer, will join us for the Q&A. Before we begin, I would like to remind you that during the course of this conference call, Xencor management may make forward-looking statements including statements regarding the company's future financial and operating results, future market conditions, the plans and objectives of management for future operations, the company's partnering efforts, capital requirements, future product offerings, research and development programs and the impacts of the COVID-19 pandemic on these topics.

  • Xencor Reports First Quarter 2020 Financial Results
    Business Wire

    Xencor Reports First Quarter 2020 Financial Results

    Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune diseases, today reported financial results for the first quarter ended March 31, 2020 and provided a review of recent business and clinical highlights.

  • Xencor to Host First Quarter 2020 Financial Results Webcast and Conference Call on May 7, 2020
    Business Wire

    Xencor to Host First Quarter 2020 Financial Results Webcast and Conference Call on May 7, 2020

    Xencor, Inc. (NASDAQ: XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune disease, today announced that it will release first quarter 2020 financial results after the market closes on Thursday, May 7, 2020.

  • Introducing Xencor (NASDAQ:XNCR), The Stock That Zoomed 109% In The Last Five Years
    Simply Wall St.

    Introducing Xencor (NASDAQ:XNCR), The Stock That Zoomed 109% In The Last Five Years

    Xencor, Inc. (NASDAQ:XNCR) shareholders might be concerned after seeing the share price drop 16% in the last quarter...

  • Hedge Funds Are Buying Xencor Inc (XNCR)
    Insider Monkey

    Hedge Funds Are Buying Xencor Inc (XNCR)

    We hate to say this but, we told you so. On February 27th we published an article with the title Recession is Imminent: We Need A Travel Ban NOW and predicted a US recession when the S&P 500 Index was trading at the 3150 level. We also told you to short the market and buy […]

  • The Daily Biotech Pulse: FDA Nod For Bristol-Myers Squibb, Xencor Licenses Tech To Vir For COVID-19 Treatment, Delay In Pfizer's Upjohn-Mylan Merger
    Benzinga

    The Daily Biotech Pulse: FDA Nod For Bristol-Myers Squibb, Xencor Licenses Tech To Vir For COVID-19 Treatment, Delay In Pfizer's Upjohn-Mylan Merger

    Here's a roundup of top developments in the biotech space over the last 24 hours:Scaling The Peaks (Biotech stocks that hit 52-week highs March 25.) * Ra Pharmaceuticals Inc (NASDAQ: RARX)Down In The Dumps (Biotech stocks that hit 52-week lows March 25.) * Anixa Biosciences Inc (NASDAQ: ANIX) * IMMUTEP LTD/S ADR (NASDAQ: IMMP) (reacted to breast cancer trial readout) * PLx Pharma Inc (NASDAQ: PLXP) * Taro Pharmaceutical Industries Ltd. (NYSE: TARO)Stocks In Focus Quidel COVID-19 Detection Assay Obtains Expanded EUA, CE Mark Approval Quidel Corporation (NASDAQ: QDEL) said its Lyra SARS-CoV-2 Assay has received expanded Emergency Use Authorization from the FDA to allow testing with three additional thermocyclers, namely Applied Biosystems' 7500, Roche Holdings AG's (OTC: RHHBY) LightCycler 480 and Qiagen NV's (NYSE: QGEN) Rotor Gene Q.Quidel said the initial EUA awarded allowed qualitative detection of nucleic acid from SARS-CoV-2 in nasopharyngeal or oropharyngeal swab specimens from patients suspected of COVID-19. The expanded authorization includes nasal and nasal turbinate swabs.Quidel also said it received the CE-Mark on March 25, which will allow it market and sell the Lyra SARS-CoV-2 Assay in Europe as well as other countries that accept CE Mark.Alector Out-Licenses China Rights of AL008 In Oncology To Innovent Biologics Alector Inc (NASDAQ: ALEC) and Hong Kong-listed biopharma Innovent Biologics said they have entered into a licensing agreement to develop and commercialize an anti-SIRP-alpha antibody AL008 for the treatment of oncology indications in China.The companies did not disclose the financial terms of the deal. The agreement gives Innovent the responsibility of leading development and commercialization of the investigational compound in China, while Alector is in charge of developmental activities outside of China.See also: The Week Ahead In Biotech: Bristol-Myers, Rockwell Medical Await FDA Decisions, COVID-19 Updates In Focus Bristol-Myers Squibb Receives FDA Nod For Celgene's Multiple Sclerosis Drug Bristol-Myers Squibb Co (NYSE: BMY) announced FDA approval for ozanimod 0.92 mg as a treatment option for patients with relapsing forms of multiple sclerosis.In premarket trading Thursday, Bristol-Myers Squibb shares were adding 1.52% to $50.10.Cerecor To Test Role Of Inflammatory Cytokinin In COVID-19-Induced Acute Respiratory Distress Cerecor Inc (NASDAQ: CERC) said it plans to explore the role of an inflammatory cytokine -- LIGHT -- in patients with COVID-19-induced acute respiratory distress. It said it will use its proprietary free LIGHT assay as well as multiple assay to determine if there are differences in LIGHT levels and other inflammatory markers, including IL-18 and IFN-g, in patients with mild-to-moderate vs. severe disease with Acute Lung Injury or Acute Respiratory Distress Syndrome.Grifols To Develop Hyperimmune Globulin For COVID-19 Grifols SA - ADR (NASDAQ: GRFS) said it has entered a formal collaboration agreement with the U.S. BARDA, the FDA and other federal public health agencies to collect plasma from convalescent COVID-19 patients and process this specific plasma into a hyperimmune globulin.The company also said it will support the necessary preclinical and clinical studies to determine if anti-SARS-CoV-2 hyperimmune globulin therapy can be used to treat COVID-19 disease.In Spain, Grifols is working on a clinical trial with inactivated plasma from recovered patients through a collaboration with select donation centers and public hospitals.View more earnings on IBBThe company also said it has accelerated the development and validation of a proprietary technology transcription-mediated amplification-based diagnostic procedure to detect the virus, with a sensitivity equivalent or even superior to that of PCR test.The stock was rising 10.47% to $19.63 in premarket trading.Pfizer, Mylan Announce Delay In Merger Of Generic Businesses Pfizer Inc. (NYSE: PFE) and Mylan NV (NASDAQ: MYL) announced the proposed merger between Mylan and Pfizer's generic unit Upjohn will now close in the second half of 2020 due to the unprecedented circumstances surrounding the COVID-19 pandemic, including associated delays in the regulatory review process. The companies initially had a closing deadline of mid-2020.Biopharmx Gets Delisting Notice From NYSE American Specialty pharma company Biopharmx Corp (NYSE: BPMX) said it received a notification from NYSE American LLC on March 24 regarding its determination to delist the company's shares from the exchange. The decision is due to the company's non-compliance with certain continued listing standards.Biopharmx said it will appeal the delisting notice. The shares, according to the company, will continue to trade on the exchange during the appeal period.The company also clarified that the delisting does not affect its business operations, its intention to merge with Timber Pharma announced Jan. 28 or its SEC reporting requirements,The stock was down 2.83% at 28 cents at the time of publication.Xencor, Vir Agree To License Technology To Extend Half-Life Of COVID-19 Treatment Candidates Xencor Inc (NASDAQ: XNCR) said it entered into a technology license agreement with Vir Biotechnology Inc (NASDAQ: VIR) that provides Vir non-exclusive access to Xencor's Xtend Fc technology to extend the half-life of novel antibodies Vir is investigating as a potential treatment for COVID-19."Xtend Fc technology has demonstrated, in multiple antibodies and through numerous human clinical trials, the ability to extend antibody drug half-life and reduce dosing frequency in patients, an important feature in anti-viral therapy for pandemic use," Xencor CEO Bassil Dahiyat said in a statement. The companies did not disclose the financial terms of the deal.Vir shares were trading 3.22% higher at $31.74 in Thursday's premarket session.Earnings Biocept Inc's (NASDAQ: BIOC) fourth-quarter revenue climbed 108% year-over-year to $1.8 million. The net loss narrowed significantly from $1.43 per share to 20 cents per share. Analysts estimated a loss of 10 cents per share.The stock was trading 8.57% higher at 38 cents at the time of publication. On The Radar PDUFA Dates IntelGenx Technologies Corp.'s (OTC: IGXT) NDA for rizaport versafilm for the treatment of acute migraine is pending before the FDA, with the target action day fixed for Thursday. The company had faced three rejections for the investigational drug in the past.Earnings * Celsion Corporation (NASDAQ: CLSN) (before the market open) * Entera Bio Ltd (NASDAQ: ENTX) (before the market open) * TFF Pharmaceuticals Inc (NASDAQ: TFFP) (before the market open) * IGM Biosciences Inc (NASDAQ: IGMS) (after the close) * NovaBay Pharmaceuticals, Inc. (NYSE: NBY) (after the close) * Vermillion, Inc. (NASDAQ: VRML) (after the close) * aTyr Pharma Inc (NASDAQ: LIFE) (after the close)Related Link: Hoth Therapeutics Shares Jump On COVID-19 Vaccine Development Plans See more from Benzinga * The Daily Biotech Pulse: Milestone Pharma Flunks Late-Stage Study, CytomX Strikes Cancer Drug Collaboration, BARDA Grant For GenMark's COVID-19 Test(C) 2020 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.

  • Xencor and Vir Biotechnology Enter License Agreement for Use of Xtend™ XmAb® Antibody Technology in Investigational Antibodies to Treat COVID-19
    Business Wire

    Xencor and Vir Biotechnology Enter License Agreement for Use of Xtend™ XmAb® Antibody Technology in Investigational Antibodies to Treat COVID-19

    Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered monoclonal antibodies for the treatment of cancer and autoimmune disease, today announced it has entered into a technology license agreement with Vir Biotechnology, Inc., in which Vir will have non-exclusive access to Xencor’s Xtend™ Fc technology to extend the half-life of novel antibodies that Vir is investigating as potential treatments for patients with COVID-19, the disease caused by the novel coronavirus SARS-CoV-2.

  • MorphoSys BLA for Cancer Drug Gets Priority Review from FDA
    Zacks

    MorphoSys BLA for Cancer Drug Gets Priority Review from FDA

    MorphoSys (MOR) BLA for blood cancer drug gets Priority Review from the FDA.

  • Thomson Reuters StreetEvents

    Edited Transcript of XNCR earnings conference call or presentation 24-Feb-20 9:30pm GMT

    Q4 2019 Xencor Inc Earnings Call

  • How Should Investors Feel About Xencor, Inc.'s (NASDAQ:XNCR) CEO Pay?
    Simply Wall St.

    How Should Investors Feel About Xencor, Inc.'s (NASDAQ:XNCR) CEO Pay?

    In 2005 Bassil Dahiyat was appointed CEO of Xencor, Inc. (NASDAQ:XNCR). This analysis aims first to contrast CEO...

  • Xencor (XNCR) Reports Q4 Loss, Lags Revenue Estimates
    Zacks

    Xencor (XNCR) Reports Q4 Loss, Lags Revenue Estimates

    Xencor (XNCR) delivered earnings and revenue surprises of 9.62% and -47.76%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

  • After peanut allergy drug approval, Peninsula biotech munches sweet $200M deal
    American City Business Journals

    After peanut allergy drug approval, Peninsula biotech munches sweet $200M deal

    The company also lined up a potential $400 million licensing deal for an experimental food allergy drug.

  • Gilead (GILD) Inks License Deal with Xencor for HIV Candidate
    Zacks

    Gilead (GILD) Inks License Deal with Xencor for HIV Candidate

    Gilead Sciences (GILD) entered into a technology license agreement with Xencor for use of XmAb antibody technologies in investigational agents for HIV.

  • Biotech Stocks Could Soar In 2020 On CRISPR Gene Editing And Precision Medicine
    Investor's Business Daily

    Biotech Stocks Could Soar In 2020 On CRISPR Gene Editing And Precision Medicine

    Biotech stocks are now the top-ranked industry group based on price performance thanks to new technology and deals. Look for new cancer drugs and genetic medicines in 2020.

  • How Xencor, Inc. (NASDAQ:XNCR) Can Impact Your Portfolio Volatility
    Simply Wall St.

    How Xencor, Inc. (NASDAQ:XNCR) Can Impact Your Portfolio Volatility

    If you're interested in Xencor, Inc. (NASDAQ:XNCR), then you might want to consider its beta (a measure of share price...

  • Company News For Dec 30, 2019
    Zacks

    Company News For Dec 30, 2019

    Companies in the news are: MIK, XNCR, PT, FCEL

  • Here is What Hedge Funds Think About Xencor Inc (XNCR)
    Insider Monkey

    Here is What Hedge Funds Think About Xencor Inc (XNCR)

    It seems that the masses and most of the financial media hate hedge funds and what they do, but why is this hatred of hedge funds so prominent? At the end of the day, these asset management firms do not gamble the hard-earned money of the people who are on the edge of poverty. Truth […]

  • Is Xencor, Inc. (NASDAQ:XNCR) Trading At A 44% Discount?
    Simply Wall St.

    Is Xencor, Inc. (NASDAQ:XNCR) Trading At A 44% Discount?

    How far off is Xencor, Inc. (NASDAQ:XNCR) from its intrinsic value? Using the most recent financial data, we'll take a...